6 May, 2016 | ChargePoint Technology
More than 200 of the region’s makers gathered at Bolton Whites Hotel for the awards, and the standard of entries was “fantastic, a real showcase in innovation, ambition and vision”, according to Miri Thomas, editorial director at Insider.
Chargepoint Technology faced competition from Milliken European Airbag Products, TALL Security Print, United Automation, Innovative Technology, Group55 and The Printed Cup Company.
Award judges recognised ChargePoint Technology’s excellent overseas sales performance for the year January to December 2015.
In making their decision, judges noted: “The BioPharma industry is highly risk-averse and does not quickly adopt new technologies so to trade in the pharma market abroad is understandably difficult. But ChargePoint has been successful in achieving technical acceptance.”
The company’s international sales last year were £6,770,565 and the company is estimating further growth in this current year.
Chris Eccles, Managing Director said: “We are certainly going in the right direction and have just returned from Interphex in New York, which is the main North American trade show of the year, where there was considerable interest in our products and where we achieved further sales.
“We are estimating further overseas sales growth of more than 15% in the next year. This is not only a real testament of the quality of our products, but of the whole team from shop floor to sales team and we are delighted that this has been recognised by winning this prestigious award, especially against such other excellent companies.”
The company’s growth in the last year has been driven by healthy sales of its existing products in the USA Europe and Asia, but also by the global roll out of a patented new AseptiSafe valve system which has taken the company into the biopharma market.
ChargePoint’s Technology’s biggest marketplace is the USA, where it achieved 20% of revenues from customers include that Merck, Roche Genentech and Johnson & Johnson while in Central Europe sales have been led by Switzerland, Germany and Belgium from pharma heavyweights such as Roche, Pfizer, Novartis, Teva and Sanofi.